Why Altitude Training Doesn't Work the Same for Everyone: Understanding Individual EPO Response

Altitude training has built a near-mythical reputation in endurance sport — elite Kenyan runners, Tour de France contenders, and Olympic distance swimmers all chase the thin air of elevation blocks to gain a hematological edge. Yet a consistent and inconvenient finding runs through decades of research: individual variation in EPO response to altitude is enormous. Some athletes emerge from a three-week camp with dramatically elevated red blood cell mass and a clear performance boost. Others finish the same block with almost nothing to show for it. Understanding why — and what to do about it — is one of the most practically important questions in applied sports physiology.

How Wide Is the EPO Response Distribution?

The landmark work that put the "non-responder" problem squarely on the map came from the U.S. Olympic Committee's live-high, train-low (LHTL) studies led by Ben Levine and Jim Stray-Gundersen in the 1990s. Their 1997 Journal of Applied Physiology paper reported that roughly 25–50% of athletes showed little or no meaningful increase in red blood cell volume after a four-week LHTL block at 2,500 m, despite following identical protocols.

Subsequent research has consistently replicated this spread:

A 2006 review by Chapman et al. found that EPO concentrations at altitude ranged from a 20% to a 400% increase above baseline across athletes living at the same elevation under controlled conditions.
Wachsmuth et al. (2013) tracked total hemoglobin mass (tHb) across a three-week camp at 2,320 m and found individual gains spanning from −1% to +10%, with a coefficient of variation far exceeding what could be explained by measurement error.
Hauser et al. (2016) confirmed that roughly one-third of recreational and competitive endurance athletes qualify as "low responders" by the conventional threshold of a less than 1% increase in tHb per week of altitude exposure.

The practical implication is stark: two athletes on the same altitude training plan, with similar fitness levels, can have fundamentally different physiological outcomes. Designing a program around average group responses will systematically underserve a large minority of athletes.

What Separates a Responder from a Non-Responder?

Researchers have identified several physiological and contextual variables that help predict who will mount a robust EPO and erythropoietic response to hypoxia.

Baseline Iron Status

Iron is the limiting nutrient for erythropoiesis. The EPO signal can be fully activated by hypoxia, but if iron stores are depleted, the bone marrow cannot synthesize new hemoglobin regardless of how loudly the hormonal signal is broadcast.

Key markers to assess before any altitude block:

Serum ferritin — the primary storage indicator; levels below 30–35 µg/L in female athletes and below 40 µg/L in male athletes are associated with blunted altitude response. Some researchers advocate for a higher threshold of ≥50 µg/L before traveling to altitude.
Transferrin saturation — a measure of iron immediately available for erythropoiesis; values below 20% suggest functional iron deficiency even when ferritin appears adequate.
Soluble transferrin receptor (sTfR) — elevated sTfR indicates tissue-level iron demand is outpacing supply, a sensitive indicator of iron-restricted erythropoiesis.

Chapman et al. (2014) directly demonstrated that athletes with higher pre-altitude serum ferritin produced greater EPO surges and larger tHb gains over a 28-day LHTL block. Iron supplementation in deficient athletes normalized this response in subsequent camps. This is arguably the single most modifiable predictor of altitude response.

Resting SpO2 and Oxygen Desaturation at Altitude

The kidney's EPO-producing cells respond to arterial oxygen tension, not altitude per se. How much arterial oxygen actually drops for a given athlete at a given elevation depends critically on pulmonary ventilation and gas exchange efficiency.

Athletes who maintain relatively high arterial oxygen saturation (SpO2) at altitude — due to efficient ventilation or favorable lung mechanics — present a weaker hypoxic stimulus to the kidneys and produce a smaller EPO surge. Paradoxically, being physiologically "good" at tolerating altitude can blunt the training adaptation.

Research benchmarks:

SpO2 of 90–93% at 2,500 m is associated with strong EPO responses in most studies.
Athletes sitting at 95–96% SpO2 at the same elevation often show attenuated EPO rises and smaller tHb gains.
Overnight desaturation (measured via overnight pulse oximetry or a sleep study) appears to provide an additional stimulus beyond daytime values; athletes who desaturate significantly during sleep may mount stronger erythropoietic responses.

This has a practical implication: a lighter elevation dose (say, 2,200 m) may be insufficient for an athlete with naturally high SpO2, who might need 2,800–3,000 m to achieve the same physiological stimulus.

Genetic Factors

A growing body of evidence points to heritable variation in several pathways governing hypoxic response.

HIF pathway polymorphisms. The hypoxia-inducible factor (HIF-1α and HIF-2α) system acts as the master oxygen sensor that drives EPO gene expression. Single nucleotide polymorphisms (SNPs) in HIF1A, EPAS1 (which encodes HIF-2α), and VHL (Von Hippel-Lindau, the protein that tags HIF for degradation under normoxia) have all been associated with differences in EPO production and erythrocyte volume in hypoxic conditions.

EPOR variations. Polymorphisms in the erythropoietin receptor gene affect the sensitivity of erythroid progenitor cells to available EPO.

Androgen sensitivity. Testosterone stimulates EPO production and erythropoiesis through androgen receptor pathways. Athletes with more responsive androgen receptor variants may show stronger erythropoietic responses; this may partly explain observed sex differences in altitude response magnitude.

Genetic testing for altitude response is not yet at the level where individual predictions are clinically reliable — the effect sizes of individual SNPs are modest and the interactions are complex. However, the genetic reality reinforces that non-response is a biological phenomenon, not a failure of effort or compliance.

How to Test Your Individual EPO Response

Before committing to repeated altitude camps, serious athletes and coaches should invest in measuring actual physiological response rather than assuming average outcomes.

Hemoglobin Mass Testing (CO Rebreathing)

The gold-standard method for quantifying erythropoietic response is carbon monoxide (CO) rebreathing, which provides a direct measure of total hemoglobin mass (tHb). A tHb measurement at sea level before and after an altitude block reveals exactly how much red blood cell volume was gained — or not.

Typical benchmarks from the literature:

A gain of ≥1% tHb per week of altitude exposure is generally accepted as a meaningful response.
A gain of <0.5% tHb per week qualifies as a low or non-response by most researchers' criteria.

CO rebreathing is available at select sports science laboratories. For athletes not near a facility, dried blood spot (DBS) testing for hemoglobin and reticulocyte percentage offers a lower-cost surrogate.

EPO Blood Testing

Serum EPO can be measured via a standard clinical blood draw. Testing at:

Sea level baseline (2–3 days before ascending)
24–48 hours post-arrival (the EPO spike peaks in this window)

A robust responder typically shows a 2- to 4-fold EPO elevation in the first 24–48 hours at altitude. An athlete who shows less than a 1.5-fold increase within 48 hours of arriving at a meaningful elevation (>2,000 m) is likely a low responder and may need protocol modification.

Reticulocyte Tracking

Reticulocytes (immature red blood cells) rise in circulation 3–5 days after the initial EPO surge. Tracking reticulocyte percentage or absolute reticulocyte count during the first week of an altitude camp provides a real-time signal of marrow response without needing specialized equipment — a standard complete blood count (CBC) panel is sufficient.

Optimizing the Protocol for Non-Responders

Being a non-responder is not a dead end. Several evidence-based strategies can improve the altitude stimulus for athletes who fail to mount a strong hematological response.

Increase the Altitude Dose

The most direct lever: live higher. If an athlete is maintaining SpO2 above 94% at 2,200 m, moving to 2,800–3,200 m will deepen the hypoxic stimulus. Most research places the threshold for meaningful EPO stimulation at a minimum of 2,100 m, with stronger responses emerging above 2,500 m. For altitude tents, targeting inspired oxygen fractions equivalent to 2,800–3,000 m may be necessary for low responders.

Optimize Iron Status Before the Block

Iron saturation before altitude exposure is the highest-yield, most actionable intervention for low responders. Protocol:

Test ferritin, transferrin saturation, and sTfR 6–8 weeks before the planned camp.
If ferritin is below 50 µg/L, initiate oral iron supplementation (ferrous sulfate or ferrous bisglycinate, 80–160 mg elemental iron on alternate days with vitamin C to enhance absorption).
Retest at 3–4 weeks to confirm stores are rising.
Continue supplementation through the altitude block and into the post-altitude period, when iron demand for erythropoiesis accelerates further.

Extend the Altitude Exposure Duration

Non-responders often show a delayed erythropoietic response. Where a strong responder may accumulate meaningful tHb gains in 2–3 weeks, a low responder may need 4–5 weeks before the bone marrow fully catches up. If time allows, extending the block duration rather than shortening it may convert a marginal response into a meaningful one.

Consider Altitude Timing in the Training Year

Altitude stress compounds overall physiological load. Athletes who arrive at altitude in a state of accumulated fatigue — depleted glycogen, elevated cortisol, suppressed immune function — produce blunted EPO responses. Scheduling altitude camps to coincide with a relatively fresh physiological state (typically early in a build phase, not immediately after a race block) improves response likelihood.

Explore Intermittent Hypoxic Exposure (IHE)

For athletes who cannot access live-high conditions and use altitude tents, intermittent hypoxic exposure protocols (brief daily sessions at simulated 4,000–5,500 m) can provide a separate non-erythropoietic hypoxic stimulus — improving ventilatory acclimatization, buffering capacity, and mitochondrial density. While IHE alone rarely drives tHb increases, it may enhance sensitivity to subsequent live-high exposure.

Practical Takeaways for Athletes and Coaches

Test before you assume. Measure ferritin and run at minimum a CBC before every altitude block. Arriving iron-deficient is the most common and preventable cause of non-response.
Measure the response, not just the protocol. CO rebreathing or reticulocyte tracking after each camp tells you whether the stimulus worked. Blindly repeating protocols that failed to produce tHb gains is a waste of time and recovery.
Individualize altitude dose. SpO2 monitoring in the first 48 hours at altitude gives immediate feedback on whether the elevation is sufficient to drive a meaningful hypoxic stimulus for that specific athlete.
Don't conflate performance outcomes with EPO response. Some athletes improve at altitude via non-hematological mechanisms — improved economy, ventilatory adaptations, psychological factors. A low EPO responder is not necessarily a poor altitude training candidate overall.
Genetic non-response is real. Communicate this clearly to athletes. Repeatedly failing to respond to altitude despite optimal iron status and elevation dose may reflect heritable biology — and redirecting investment to other training methods is a legitimate evidence-based decision.

If you want to better understand your own altitude response profile — including EPO predictors, iron status benchmarking, and altitude dose calculators — explore the tools and evidence summaries at AltitudePerformanceLab.com. Subscribe to the newsletter for weekly breakdowns of sports science research applied to real training decisions.